AKT1 and Kaposi's sarcoma: Moreover, mTOR, one of the downstream targets of the PI3K/Akt pathway, has been shown to promote survival of KSHV-infected lymphatic endothelial cells [51, 52] and treatment of transplant patients with rapamycin, a small molecule inhibitor of mTOR, can induce KS regression [53].